Mylan says it is approaching $1bn in total cumulative biosimilars sales, also disclosing during its second-quarter results call that its annual sales from biosimilars were now sitting at around $500m.
Mylan’s Biosimilars Close In On $1bn Milestone
Firm Reveals Annual Sales Total From Biosimilars Business
Mylan says it is closing in on $1bn in cumulative sales of its biosimilars, also disclosing its annual turnover figure from biosimilars as it reported its second-quarter results.
